Text Size

Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice

Chi Z.-L., Akahori M., Obazawa M., Minami M., Noda T., Nakaya N., Tomarev S., Kawase K., Yamamoto T., Noda S., Sasaoka M., Shimazaki A., Takada Y., Iwata T.

  • 2010
  • Human Molecular Genetics
View publication
  • Therapeutic Area


  • Categories

    Preclinical development

  • Affiliations

    National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan; National Eye Institute, National Institutes of Health, 5635 Fishers Lane, Rockville, MD 20852, United States; Department of Ophthalmology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan; Department of Nursing, Tokai University School of Health Sciences, Boseidai, Isehara, Kanagawa Prefecture 259-1193, Japan; Research and Development Center, Santen Pharmaceutical Co., Ltd, 8916-16, Takayama-cho, Ikoma, Nara Prefecture 630-0101, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.

Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.

The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022